Pfizer Inc. (PFE), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Decision Looms on New Multiple Sclerosis Drug

Page 1 of 2

Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec Inc. (NASDAQ:BIIB) is certainly hoping so. The biotech’s multiple sclerosis drug Tecfidera received a positive recommendation for market authorization approval from the European Union’s Committee for Medicinal Products for Human Use, or CHMP, last Friday. Next up for Tecfidera is a decision by the U.S. Food and Drug Administration due this week. A final decision in Europe will come in the next two months.

Many in the MS community are anxiously awaiting availability of Tecfidera. What’s behind the buzz — and how likely is it that the MS drug will gain approval?

Disrupting the market?
While there is no cure, several treatments are currently available for slowing the progression of multiple sclerosis.  Beta interferon drugs help prevent damage to myelin, a sheath that shields nerve fibers. Leading beta interferon drugs are Biogen’s Avonex, Betaseron from Bayer, and Rebif, which is co-marketed by EMD Serona and Pfizer Inc. (NYSE:PFE) . All three drugs are administered through injection. Common side effects include inflammation at the injection site and flu-like symptoms.

Pfizer Inc. (NYSE:PFE)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)‘ Copaxone also works by protecting myelin. Like the beta interferon drugs, Copaxone is taken via injection with one of the most common side effects relating to inflammation at the site of injection.

Another treatment that has demonstrated success with slowing progression of MS is Tysabri. Biogen and Elan Corporation, plc (ADR) (NYSE:ELN) co-market the drug for now, but the two companies recently announced a deal where Biogen would buy full rights for Tysabri for $3.25 billion. Similar to the other drugs already mentioned, Tysabri is administered through injection. It has some of the same kinds of side effects as the others, but also can increase the possibility of patients getting a rare brain infection that can lead to death or severe disability.

The inconvenience and possibility of reactions associated with these injections opened the door for commercial success of drugs that can be taken orally. Novartis‘ Gilenya was the first MS pill to gain FDA approval in 2010. Gilenya racked up 2012 sales of $1.2 billion. However, sales were dampened somewhat in early 2012 after the FDA and the European Medicines Agency announced investigations of several deaths related to heart problems in patients taking Gilenya.

Last September, the FDA approved another oral treatment for MS — Sanofi‘s Aubagio. Sanofi received good news from Europe at the same time as Biogen, getting a positive recommendation from CHMP for Aubagio last week.

However, many expect Tecfidera to become the biggest seller in the MS market with annual sales topping $3.25 billion within the next four years. With all of the treatments already available, why is there such eagerness for Biogen’s new drug? Three reasons stand out.

First, like Gilenya and Aubagio, Tecfidera is a pill and therefore won’t have the inconvenience and injection site reactions associated with most of the other available drugs. Second, the drug has demonstrated solid efficacy  – reducing patients’ annual relapse rate by nearly half. Third, Tecfidera’s safety profile looks to be better than the others, with the most common side effects including flushing and gastrointestinal effects such as nausea and diarrhea. Biogen hopes that the drug’s convenience, efficacy, and safety will score big with patients and prescribers.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!